Actively Recruiting

Phase Not Applicable
Age: 19Years - 84Years
All Genders
NCT04708587

Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)

Led by Yonsei University · Updated on 2026-01-21

900

Participants Needed

1

Research Sites

363 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.

CONDITIONS

Official Title

Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)

Who Can Participate

Age: 19Years - 84Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Over 19 years old
  • Diagnosed with chronic renal failure stage IIIb, IV, or V (CKD-EPI eGFR <45 / <30 / <15 or on dialysis)
  • Treated with a new generation drug eluting stent
  • Signed consent form
Not Eligible

You will not qualify if you...

  • Over 85 years old
  • High risk of bleeding including history of hemorrhagic stroke; stroke, dementia, or central nervous system damage within 1 year; head trauma or brain surgery within 6 months; tumor in the skull; suspected aortic dissection; internal bleeding within 6 weeks; active bleeding or bleeding disorder; major surgery, trauma, or bleeding within 3 weeks
  • Need for oral anticoagulant therapy
  • Pregnant women or women of childbearing age
  • Life expectancy less than 1 year
  • History of intracranial bleeding
  • Moderate to severe hepatic impairment (Child-Pugh class B or C)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine

Seoul, South Korea

Actively Recruiting

Loading map...

Research Team

J

Jung-Sun Kim, MD, PhD, FESC

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here